SPHK1 and hepatocellular carcinoma: Based on existing studies, combining SphK inhibitors with anti-TNF therapies, through dual targeting of intrinsic apoptotic resistance and the immunosuppressive microenvironment in HCC cells, offers a new strategy to overcome treatment resistance.